CORBUS PHARMACEUTICALS
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum i... s currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.
CORBUS PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2009-01-01
Address:
Norwood, Massachusetts, United States
Country:
United States
Website Url:
http://www.corbuspharma.com
Total Employee:
51+
Status:
Active
Contact:
(617) 963-0100
Email Addresses:
[email protected]
Total Funding:
196.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Investors List
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Corbus Pharmaceuticals
Ghost Tree Capital Group
Ghost Tree Capital Group investment in Post-IPO Equity - Corbus Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Corbus Pharmaceuticals
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Corbus Pharmaceuticals
Fort Point Angels
Fort Point Angels investment in Venture Round - Corbus Pharmaceuticals
Oleg Uritsky
Oleg Uritsky investment in Venture Round - Corbus Pharmaceuticals
SternAegis
SternAegis investment in Venture Round - Corbus Pharmaceuticals
Boston Harbor Angels
Boston Harbor Angels investment in Angel Round - Corbus Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-07 | Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.corbuspharma.com Semrush global rank: 9.44 M Semrush visits lastest month: 157
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Corbus Pharmaceuticals"
Overview : Corbus Pharmaceuticals Holdings, Inc.
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) …See details»
About Corbus Pharmaceuticals Holdings : Corbus Pharmaceuticals …
Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the …See details»
Our Company : Corbus Pharmaceuticals Holdings, Inc.
Profile : Corbus Pharmaceuticals Holdings, Inc.
Address: 500 River Ridge Drive Norwood, MA 02062 US. Telephone: 617.963.0100. Fax: 617.663.6085. Email: [email protected]See details»
Corbus Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (617) 963-0100 Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the …See details»
Overview, News & Similar companies - ZoomInfo.com
May 9, 2024 Corbus Pharmaceuticals contact info: Phone number: (617) 963-0100 Website: www.corbuspharma.com What does Corbus Pharmaceuticals do? Corbus Pharmaceuticals …See details»
Corbus Pharmaceuticals - LinkedIn
Corbus Pharmaceuticals | 15,345 followers on LinkedIn. Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines | Corbus is a precision …See details»
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief …
Feb 28, 2024 Previously, as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization, he executed clinical trials involving numerous novel …See details»
Corbus Pharmaceuticals - Craft
Oct 18, 2024 Corbus Pharmaceuticals has 5 employees at their 1 location and $881.71 k in annual revenue in FY 2021. See insights on Corbus Pharmaceuticals including office …See details»
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Stock Analysis
About CRBP. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) …See details»
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief …
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a …See details»
Leadership Team & Board of Directors
Ms. Jacques is the former President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”), a late-stage biopharmaceutical company focused on innovative …See details»
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial …
Aug 6, 2024 The increase was primarily attributable to an increase of $2.0 million in CRB-701 clinical trial costs with our contract research organization ("CRO") and clinical sites, as well as …See details»
Working at Corbus Pharmaceuticals - Zippia
Mar 14, 2024 www.corbuspharma.com. Organization Type. Public. CEO. Yuval Cohen. Social Media. Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical …See details»
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Yahoo Finance …
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the …See details»
Working Here : Corbus Pharmaceuticals Holdings, Inc.
Own compassion. Who are we looking for? Barrier breakers.You have grit and resilience because good medicine and strong science is worth fighting for. What we can offer?See details»
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial …
Aug 6, 2024 The increase was primarily attributable to an increase of $2.0 million in CRB-701 clinical trial costs with our contract research organization ("CRO") and clinical sites, as well as …See details»
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital …
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, …See details»
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public ...
NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a …See details»